drugset / Trial / NCT03941587
Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment
Completed
60 enrolled
Singapore National Eye Centre
National University Hospital, Singapore · collabTan Tock Seng Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
In this study, we aim to evaluate the efficacy and safety of an individualized dosing schedule comprising Aflibercept and RF-PDT in patients with polypoidal choroidal vasculopathy (PCV). The primary objective is to compare the polyp closure rate at week 12 between the 2 treatment groups. The secondary aims include comparing visual, anatomical, treatment burden and clinical biomarkers between each treatment group.
Timeline
- Start
- 2021-02-01
- Primary completion
- 2024-06-06
- Completion
- 2024-06-06
Publications
- Chong YJ, Teo KYC, Wong W, Tan ACS, Su X, Gilead N, Chan HH, Ibrahim F, Fenner B, Ong C, Sun C, Sim S, Chee C, Chakravarthy U, Cheung CMG. Aflibercept With vs Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2025 May 1;143(5):393-399. doi: 10.1001/jamaophthalmol.2025.0250.
- Vyas CH, Cheung CMG, Tan C, Chee C, Wong K, Jordan-Yu JMN, Wong TY, Tan A, Fenner B, Sim S, Teo KYC. Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy. BMJ Open. 2021 Jul 15;11(7):e050252. doi: 10.1136/bmjopen-2021-050252.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Comparator | Verteporfin | Other / unclassified | 6 mg/m2 | Intravenous |